| Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Despite continuous advancements in detection technologies and treatment options, its incidence and mortality rates remain high, posing a serious threat to patients’ health. In recent years, the rapid development of immunotherapy has provided survival benefits for NSCLC patients with driver gene-negative tumors and those who are resistant to targeted therapies, making it an emerging focus of research in the field of lung cancer. However, the efficacy of immunotherapy is influenced by various factors, highlighting the importance of accurately identifying patients who are most likely to benefit from it. Therefore, this article reviews the factors affecting the efficacy of immunotherapy in NSCLC and summarizes the predictive models based on these factors. |
